Pluristem adds South Korea to list of countries participating in IC study

Pluristem Therapeutics (PSTI) gets South Korean regulatory approval to conduct a Phase 2 study of PLX-PAD cells in Intermittent Claudication.

South Korea is the fourth country to participate in the multinational trial. (PR)

From other sites
Comments (1)
  • jimcoe
    , contributor
    Comments (51) | Send Message
    Sometimes it seems that these biotec stories take forever to
    get anywhere.But someday all the parts will fall into place and
    a magnificent company will come forth.Stay the course to get
    the 10 or 20 bagger.
    13 Nov 2013, 08:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs